These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 24782154

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
    Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, Soma K, Wang L, Riese R.
    Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
    Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y.
    Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
    [Abstract] [Full Text] [Related]

  • 11. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
    Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R.
    Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
    [Abstract] [Full Text] [Related]

  • 12. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
    Abdulrahim H, Sharlala H, Adebajo AO.
    Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
    [Abstract] [Full Text] [Related]

  • 13. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C, Conaghan PG.
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [Abstract] [Full Text] [Related]

  • 14. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV.
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
    Ann Intern Med; 2013 Aug 20; 159(4):I-26. PubMed ID: 24026272
    [No Abstract] [Full Text] [Related]

  • 17. [JAK inhibitor].
    Yamaoka K, Tanaka Y.
    Nihon Rinsho; 2013 Jul 20; 71(7):1243-7. PubMed ID: 23961674
    [Abstract] [Full Text] [Related]

  • 18. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K, Tanaka Y.
    Nihon Rinsho Meneki Gakkai Kaishi; 2015 Jul 20; 38(6):443-7. PubMed ID: 27118331
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
    Varisco PA, So A.
    Rev Med Suisse; 2014 Jan 22; 10(414):187-91. PubMed ID: 24624736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.